Qiagen N.V.

  • WKN: A2DKCH
  • ISIN: NL0012169213
  • Land: The Netherlands

Nachricht vom 19.10.2021 | 11:14

QIAGEN N.V.: Release of a capital market information

QIAGEN N.V. / Share Repurchase
19.10.2021 / 11:14
Dissemination of a Post-admission Duties announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Disclosure according to Article 5 Section (1) and (6) of the EU Regulation 596/2014 in conjunction with Article 2 Section (2) and (3) of the Delegated EU Regulation 2016/1052 / Share Repurchase - Interim Reporting

With disclosure dated September 22, 2021, QIAGEN N.V. announced pursuant to Article 5 Section (1) and (6) of the EU Regulation no 596/2014 and Article 2 Section (1) of the Delegated EU Regulation no 2016/1052 the beginning of a second tranche of up to USD 19.4 million starting on September 27, 2021 under the share repurchase program originally announced on July 12, 2021.

The number of shares which have been bought back within the framework of such tranche of the share repurchase program in the time period from October 11, 2021 until and including October 15, 2021, amounts to 96,894 shares.

Shares were bought back as follows:

Date Number of Shares acquired Average Price (EUR) Purchased Volume (EUR)
11- October -2021 4,000 44.2008 176,803.20
12- October -2021 70,000 44.4627 3,112,389.00
13- October -2021 11,894 44.4851 529,105.78
14- October -2021 10,000 44.6603 446,603.00
15- October -2021 1,000 44.6105 44,610.50
Total 96,894 44.4766 4,309,511.48
 

The underlying individual trades are published on the website of QIAGEN N.V. (https://corporate.qiagen.com/investor-relations/stock-information/share-buyback/default.aspx).

The total number of shares which have already been bought back within the framework of such tranche of the share repurchase program from September 27, 2021 until and including October 15, 2021 amounts to 318,557 shares.

The purchase of the shares of QIAGEN N.V. was carried out by a financial institution that has been commissioned by QIAGEN N.V.

Venlo, 19 October 2021

Managing Board

###
Contacts:

QIAGEN

Investor Relations   Public Relations  
John Gilardi +49 2103 29 11711 Dr. Thomas Theuringer +49 2103 29 11826
e-mail: ir@qiagen.com   e-mail: pr@qiagen.com  


19.10.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Symrise verlängert Vorstandsvertrag von Dr. Heinz-Jürgen Bertram vorzeitig bis 2025

01. Dezember 2021, 15:38

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

Bio-Gate AG

Original-Research: Bio-Gate AG (von GBC AG): Kaufen

02. Dezember 2021